Reactive Oxygen Species Is Essential for Cycloheximide to Sensitize Lexatumumab-Induced Apoptosis in Hepatocellular Carcinoma Cells
2011

Combining Lexatumumab and Cycloheximide to Induce Apoptosis in Liver Cancer Cells

publication 10 minutes Evidence: moderate

Author Information

Author(s): Zhao Xiangxuan, Cao Mengde, Liu Joy J., Zhu Haizhen, Nelson David R., Liu Chen

Primary Institution: University of Florida College of Medicine

Hypothesis

Can cycloheximide sensitize hepatocellular carcinoma cells to lexatumumab-induced apoptosis?

Conclusion

The combination of lexatumumab and cycloheximide effectively induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species generation.

Supporting Evidence

  • Combination treatment with lexatumumab and cycloheximide significantly increased apoptosis in HCC cells.
  • Reactive oxygen species generation was crucial for the apoptosis induced by the combination treatment.
  • Normal human hepatocytes were not affected by the combination treatment, indicating selectivity for cancer cells.

Takeaway

This study shows that a drug called lexatumumab can kill liver cancer cells better when used with another drug called cycloheximide, which helps the first drug work better.

Methodology

The study involved treating hepatocellular carcinoma cell lines with lexatumumab and cycloheximide, followed by various assays to measure apoptosis and reactive oxygen species levels.

Limitations

The study primarily focuses on specific cell lines and may not fully represent the complexity of liver cancer in patients.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016966

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication